National Institutes of Health Update

Claire Schuster, MPH
National Institute of Allergy and Infectious Diseases
National Institutes of Health
December 2020

mRNA-1273 Vaccine in Older Adults

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

ACTIV 1-4

• ACTIV-1: An adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19 (infliximab, abatacept, Cenicriviroc).
• ACTIV-2: An outpatient Phase 2 clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies to treat the disease.
• ACTIV-3: An inpatient Phase 3 randomized, controlled trial that provides a “master protocol” to test multiple different kinds of monoclonal antibody treatments. (Sub-study closed on Oct. 26)
• ACTIV-4: A “master protocol” to evaluate the safety and effectiveness of different types of blood thinners to treat patients with diagnosed COVID-19.

Selected COVID-19 Vaccine Candidates

<table>
<thead>
<tr>
<th>Platform</th>
<th>Developer</th>
<th>Phase 1/2</th>
<th>Phase 2/3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucleic acid</td>
<td>moderna</td>
<td>Enrolled</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td>biontech</td>
<td>Enrolled</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Viral vector</td>
<td>COVID19</td>
<td>Enrolled</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td>pfizer</td>
<td>Enrolled</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Protein subunit</td>
<td>merck</td>
<td>Ongoing</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>novavax</td>
<td>Ongoing</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td>sanofi</td>
<td>Ongoing</td>
<td>--</td>
</tr>
</tbody>
</table>

Updated: November 6, 2020

ACTIV-5/Big Effect Trial

NIH Study Aims To Identify Promising COVID-19 Treatments for Larger Clinical Trials

Acute Flaccid Myelitis Update

NIH Awards Contract to Develop Enterovirus-D68 Vaccine

Growing concerns about global spread of this respiratory enterovirus

NIH awarded contract to Intravacc for development of inactivated EV-D68 vaccine candidate

Vaccine aims to protect children from Acute Flaccid Myelitis (AFM)
Childhood Pneumonia Study Shows Short-Course Antibiotics Superior to Standard of Care

- NIAID-sponsored randomized, double-blind, placebo-controlled trial
- 5 day antibiotic treatment is superior to standard (10 day) treatment of community-acquired pneumonia (CAP) in children 6 months to 5 years.